Neuroendocrine carcinoma of the prostate is a rare and aggressive form of prostate cancer that requires specialized treatment approaches. Understanding the available therapies—both standard and those being researched in clinical trials—can help patients and their families navigate this challenging diagnosis.

Managing a Rare and Aggressive Disease: Treatment Goals and Approaches

When someone receives a diagnosis of neuroendocrine carcinoma of the prostate, the primary treatment goals focus on slowing disease progression, managing symptoms, and maintaining quality of life for as long as possible. This form of prostate cancer behaves very differently from the more common prostate adenocarcinoma (the typical glandular prostate cancer), and therefore requires distinct treatment strategies^[1].

Treatment decisions depend heavily on the stage at which the disease is diagnosed, the extent of its spread throughout the body, and the patient’s overall health condition. Unfortunately, neuroendocrine prostate cancer is often discovered at an advanced stage because it tends to grow and spread quickly. In many cases, patients already have metastatic disease (cancer that has spread to other organs or bones) by the time symptoms appear^[6].

Medical teams rely on treatment protocols established by cancer societies and healthcare guidelines, which represent the current standard of care. At the same time, researchers around the world are actively investigating new therapies through clinical trials. These studies explore innovative approaches that might offer better outcomes for patients facing this aggressive disease. The scientific community recognizes that improving treatment for neuroendocrine prostate cancer is an urgent need, given its poor prognosis and limited response to conventional prostate cancer treatments^[7].

Standard Treatment Approaches: What Doctors Currently Use

The cornerstone of standard treatment for neuroendocrine carcinoma of the prostate is platinum-based chemotherapy, which is borrowed from the treatment approach used for small cell lung cancer because these two diseases share similar biological features. The most commonly used combination includes two specific drugs: cisplatin (or sometimes carboplatin) paired with etoposide. This chemotherapy regimen works by damaging the DNA of rapidly dividing cancer cells, preventing them from multiplying^[6].

This platinum-etoposide combination has been the first-line standard treatment for years because it can be effective against neuroendocrine prostate cancer. When patients respond to this therapy, they may experience shrinkage of tumors and improvement in symptoms. However, the disease typically responds only temporarily, and the cancer often begins growing again after several months. The average response duration is limited, which presents a significant challenge for both patients and their medical teams^[10].

Treatment typically continues for several cycles, usually administered every three weeks in an outpatient setting. The exact duration depends on how well the cancer responds and how well the patient tolerates the side effects. Doctors carefully monitor blood counts and organ function throughout treatment because chemotherapy affects not only cancer cells but also healthy, rapidly dividing cells in the body^[10].

The side effects of platinum-based chemotherapy can be substantial and impact daily life. Patients commonly experience nausea and vomiting, which can usually be managed with anti-nausea medications. Bone marrow suppression is another significant concern—this means the chemotherapy reduces the production of blood cells, leading to anemia (low red blood cells causing fatigue), neutropenia (low white blood cells increasing infection risk), and thrombocytopenia (low platelets increasing bleeding risk). Other side effects include hair loss, fatigue, loss of appetite, nerve damage causing tingling or numbness in hands and feet, and kidney damage, particularly with cisplatin^[10].

After the initial chemotherapy stops working or if the cancer progresses despite treatment, second-line treatment options become much more limited and generally less effective. Some patients may receive other chemotherapy drugs such as docetaxel, which is commonly used for typical prostate cancer, or drugs like amrubicin or irinotecan. Unfortunately, studies show that these second-line treatments typically provide only modest benefits, with progression-free survival often measuring three months or less^[10].

One important distinction is that neuroendocrine prostate cancer typically does not respond to the androgen deprivation therapy (hormone therapy) that works well for common prostate adenocarcinoma. This is because neuroendocrine cancer cells have lost their dependence on the androgen receptor signaling pathway. In other words, these cancer cells no longer need male hormones like testosterone to grow, which is why treatments that block these hormones are generally ineffective. The tumors often show low or absent levels of PSA (prostate-specific antigen) and do not express the androgen receptor, making them fundamentally different from typical prostate cancer^[1].

In some cases where the cancer has spread to bones, doctors may recommend bisphosphonates or other bone-strengthening medications to reduce the risk of fractures and manage bone pain. Radiation therapy may also be used to target specific areas of disease, particularly to relieve pain from bone metastases or to address symptoms caused by tumor growth in specific locations. These are considered palliative approaches, meaning they aim to improve comfort and quality of life rather than cure the disease^[9].

Innovative Treatments Being Studied in Clinical Trials

The limited effectiveness of current standard treatments has driven researchers to explore new therapeutic approaches through clinical trials. Scientists have made significant progress in understanding the molecular and genetic changes that occur when prostate cancer transforms into neuroendocrine carcinoma, and these discoveries are pointing toward potential new treatment targets^[7].

One important finding is that neuroendocrine prostate cancer often involves the loss of specific tumor suppressor genes, particularly RB1 and TP53. These genes normally act as brakes on cell division, and when they are lost or damaged, cells can divide uncontrollably. This loss appears to facilitate a process called lineage plasticity, where prostate cancer cells essentially change their identity, adopting characteristics of neuroendocrine cells. Understanding this transformation has opened new avenues for research^[1].

Several innovative treatment approaches are currently being investigated in clinical trials around the world, including in the United States, Europe, and other regions. Immunotherapy represents one promising avenue of research. Immune checkpoint inhibitors are drugs that help the body’s immune system recognize and attack cancer cells. Researchers are testing whether these medications, which have shown success in other cancers, might benefit patients with neuroendocrine prostate cancer. These trials typically enroll patients in Phase I (testing safety) or Phase II (testing effectiveness) studies^[7].

Another area of active investigation involves PARP inhibitors (poly ADP-ribose polymerase inhibitors). These drugs interfere with cancer cells’ ability to repair damaged DNA. Research suggests that some patients with neuroendocrine prostate cancer who have alterations in genes involved in DNA repair—specifically homologous recombination repair genes—might benefit from PARP inhibitor treatment. When cancer cells already have defects in DNA repair, adding a PARP inhibitor can overwhelm their remaining repair mechanisms, causing the cells to die. Clinical trials are exploring this targeted approach in carefully selected patient populations^[10].

Researchers are also investigating drugs that target the epigenetic changes characteristic of neuroendocrine prostate cancer. Epigenetic changes are modifications that affect how genes are turned on or off without changing the DNA sequence itself. One protein called EZH2 is often overexpressed in neuroendocrine prostate cancer and plays a role in silencing genes that would normally suppress tumor growth. Scientists are testing EZH2 inhibitors to see if blocking this protein can slow cancer progression. These studies examine the mechanism of action at the molecular level, attempting to reverse the epigenetic reprogramming that drives neuroendocrine transformation^[1].

Molecularly targeted therapies aimed at specific pathways activated in neuroendocrine prostate cancer are also under investigation. For example, researchers are studying drugs that target transcription factors like SOX2, ASCL1, and BRN2, which are proteins that control the expression of genes associated with neuroendocrine characteristics. While directly targeting these proteins has proven technically challenging, scientists are exploring ways to interfere with the pathways they control or to target other proteins they depend on^[1].

Some clinical trials are testing combination approaches that pair traditional chemotherapy with newer targeted agents or immunotherapy drugs. The rationale is that attacking the cancer through multiple mechanisms simultaneously might improve outcomes compared to single-agent therapy. Early phase trials are carefully evaluating these combinations to determine the optimal doses and schedules while monitoring for unexpected side effects^[7].

A specialized radiation approach called stereotactic ablative radiotherapy or SABR is also being studied. This technique delivers very high doses of precisely targeted radiation to cancer sites while sparing surrounding healthy tissue. Some case reports have described patients with treatment-related neuroendocrine prostate cancer managed with partial SABR achieving prolonged survival, though this approach requires further study in larger patient groups^[9].

Clinical trials for neuroendocrine prostate cancer often have specific eligibility requirements. Patients typically need to have tissue confirmation of the neuroendocrine histology through biopsy. Many trials also require information about specific genetic alterations in the tumor, which can be obtained through genomic testing. Some studies are open to patients who have already received standard platinum-based chemotherapy and progressed, while others may accept newly diagnosed patients. Trial locations vary, with studies being conducted at major cancer centers throughout North America, Europe, and other regions. Patients interested in clinical trials should discuss options with their oncologist, who can help determine which studies might be appropriate and assist with enrollment processes^[7].

Most Common Treatment Methods

• Platinum-based chemotherapy
  • Combination of cisplatin or carboplatin with etoposide as first-line standard treatment
  • Borrowed from small cell lung cancer treatment protocols due to biological similarities
  • Administered in cycles, typically every three weeks
  • Can cause significant side effects including nausea, bone marrow suppression, fatigue, and nerve damage
• Second-line chemotherapy
  • Docetaxel, previously used for prostate adenocarcinoma
  • Amrubicin and irinotecan as alternative options
  • Generally less effective with shorter progression-free survival, typically three months or less
• Supportive and palliative care
  • Radiation therapy for symptom relief, particularly for bone pain
  • Bone-strengthening medications like bisphosphonates for metastatic bone disease
  • Pain management strategies
• Immunotherapy (in clinical trials)
  • Immune checkpoint inhibitors being tested in Phase I and Phase II studies
  • Aim to activate the immune system to recognize and attack cancer cells
• PARP inhibitors (in clinical trials)
  • Targeted treatment for patients with homologous recombination repair gene alterations
  • Work by interfering with DNA repair mechanisms in cancer cells
  • Being studied in selected patient populations with specific genetic characteristics
• Epigenetic-targeted therapies (in clinical trials)
  • EZH2 inhibitors targeting overexpressed proteins involved in gene silencing
  • Attempt to reverse the epigenetic changes that drive neuroendocrine transformation